# Clene (NASDAQ: CLNN) CEO Discusses CNM-Au8(R) Trial Results on BioMedWire Podcast

* Clene is pioneering a very unique approach to the treatment of neurodegenerative diseases such as ALS and MS with the use of an oral nanotherapeutic that can be easily administered
* The company has submitted CNM-Au8 biomarker and efficacy data to the Food and Drug Administration in a Type C meeting request, seeking approval to file a new drug application using the accelerated approval pathway for ALS
* CNM-Au8 has the potential to impact the ALS therapeutic market, as CNM-Au8 can help increase and improve survival rates and delay clinical worsening in ALS patients
* In MS, CNM-Au8 can work in conjunction with current treatments to improve vision, cognition, and global neural function in MS patients, potentially capturing a significant portion of the MS market as well

 Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, was recently featured on The BioMedWire Podcast, highlighting the important results of CNM-Au8 trials for both amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), and plans for the future (https://ibn.fm/6OOO1).

 During the podcast, CEO Rob Etherington explained that Clene is focused entirely on improving mitochondrial health and protecting neuron function, which is “the most important thing we can do to…

 Read More>>

 NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

 Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

 The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

 Corporate Communications

 IBN (InvestorBrandNetwork)Los Angeles, Californiawww.InvestorBrandNetwork.com310.299.1717 OfficeEditor@InvestorBrandNetwork.com 

[Original/Source Press Release](https://rss.investorbrandnetwork.com/ult-prem/clene-nasdaq-clnn-ceo-discusses-cnm-au8r-trial-results-on-biomedwire-podcast/)
                    

[Newsramp.com TLDR](None) 

https://www.reddit.com/r/HealthCareNewsInfo/comments/1f4oomq/clenes_cnmau8_trials_show_promise_for_als_and_ms/